カタログ製品コード : C-EK11172
Human VEGF R1/Flt-1 ELISA kit
| 24T | ¥55,200 | (¥2,300/T) (税別) |
| 48T | ¥69,200 | (¥1,442/T) (税別) |
| 96T | ¥78,000 | (¥813/T) (税別) |
標準納期 : 2週間 |
製品詳細
| メーカー名 | 遺伝子名 | 種交差性 | 測定範囲 | サンプル量 | 適用サンプル | ドキュメント |
|---|---|---|---|---|---|---|
| MultiSciences | VEGF R1/Flt-1 | Human | 156.25 - 10000 pg/ml | 20 μl | 血清、血漿、細胞培養上清 |
|
■保存方法 :
キットは未開封の場合、4℃で保管すること。 開封後は標準溶液を-20℃で保存し、他の試薬は4℃で保存すること。
■構成内容 :
| 96-well polystyrene microplate coated with a monoclonal antibody against VEGF R1 |
| Human VEGF R1 Standard, lyophilized |
| VEGF R1 Detect Antibody |
| Standard Diluent |
| Streptavidin-HRP |
| Assay Buffer (10×) |
| Substrate (TMB) |
| Stop Solution |
| Washing Buffer (20×) |
| Plate Covers |
■キーワード :
Homo sapiens,Human,Vascular endothelial growth factor receptor 1,VEGFR-1,Fms-like tyrosine kinase 1,FLT-1,Tyrosine-protein kinase FRT,Tyrosine-protein kinase receptor FLT,Vascular permeability factor
■ターゲット情報 :
This assay employs the quantitative sandwich enzyme immunoassay technique for the quantitative detection of human VEGF R1. The Human VEGF R1/Flt-1 ELISA is for research use only. Not for diagnostic or therapeutic procedures.
Vascular endothelial growth factor receptor-1 (VEGF R1), also known as Flt-1, is a receptor tyrosine kinase (RTK) specific for the angiogenic factors VEGF (VEGF-A), PlGF, and VEGF-B. There are two forms: membrane - bound (mbVEGFR) and soluble (sVEGFR), depending on alternative splicing.
Experimental and clinical administrations of sVEGF R1 have been employed successfully in the prevention of neovasculogenesis and tumor growth. The serum/plasma level of sVEGF R1 may vary by pathology, and may have prognostic value. It has been suggested that sVEGF R1 levels should be presented alongside VEGF levels in experimental and pathological conditions. High levels of sVEGF R1 reportedly occur in the plasma during pregnancy and in patients with essential hypertension. Significantly lower levels have been observed in the plasma of patientswith cardiovascular disease and in smokers.
